Lenvatinib mesylate（LEN）是一种口服酪氨酸激酶抑制剂，用于治疗多种癌症，包括肝细胞癌（HCC）。LEN治疗HCC与非常高的不良事件发生率相关，尤其是甲状腺功能减退。本研究通过分析接受LEN治疗的HCC患者的临床实验室数据，调查了LEN引起的甲状腺功能减退的发生率以及与患者人口统计学特征之间的关系。这是一项单中心的回顾性研究，研究对象为2018年4月19日至2020年9月30日期间接受LEN治疗的HCC患者。观察期从LEN治疗开始前一周到治疗结束后一个月。共招募了61名HCC患者。高级别甲状腺功能减退（CTCAE第2-3级）在61名患者中发现有36.1%（22/61名患者）发生。在高级别甲状腺功能减退中，嗜酸性粒细胞（EOSINO）计数明显降低（p = 0.029）。EOSINO计数的截断值估计约为150/µL。目前吸烟和EOSINO计数<150/µL对高级别甲状腺功能减退的调整后的比值比分别为0.237（95%置信区间：0.063-0.893）和4.219（95%置信区间：1.119-15.92）。研究结果显示，非吸烟和EOSINO计数<150/µL是LEN引起的高级别甲状腺功能减退的危险因素。© 2023 S. Karger AG, Basel.

Lenvatinib mesylate (LEN) is an orally administered tyrosine kinase inhibitor used for the treatment of various cancers, including hepatocellular carcinoma (HCC). HCC treatment with LEN is associated with a very high incidence of adverse events, especially hypothyroidism. This study investigated the incidence of hypothyroidism due to LEN and the relationships between hypothyroidism incidence and patient demographics by analyzing clinical laboratory data from HCC patients treated with LEN.This was a single-center, retrospective study of HCC patients who received LEN between April 19, 2018, and September 30, 2020. The observation period was from 1 week before the start of LEN administration to 1 month after the end of administration.In total, 61 patients with HCC were enrolled. High-grade hypothyroidism (CTCAE Grade 2-3) was found in 36.1% (22/61 patients). In high-grade hypothyroidism, eosinophil (EOSINO) count was significantly low (p = 0.029). The cutoff value of EOSINO count was estimated to be approximately 150/µL. The adjusted odds ratios of high-grade hypothyroidism for current smoking and EOSINO count <150/µL were 0.237 (95% confidence interval: 0.063-0.893) and 4.219 (95% confidence interval: 1.119-15.92), respectively.The results showed that noncurrent smoking and EOSINO count <150/µL are risk factors for LEN-induced high-grade hypothyroidism.© 2023 S. Karger AG, Basel.